These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Engelborghs S Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466 [TBL] [Abstract][Full Text] [Related]
4. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807 [TBL] [Abstract][Full Text] [Related]
5. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476 [TBL] [Abstract][Full Text] [Related]
6. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736 [TBL] [Abstract][Full Text] [Related]
7. [Cerebrospinal fluid biomarkers of Alzheimer's disease in current clinical practice]. Magnin E; Popp J Rev Med Suisse; 2016 Apr; 12(515):791-4. PubMed ID: 27276722 [TBL] [Abstract][Full Text] [Related]
8. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875 [TBL] [Abstract][Full Text] [Related]
9. No added diagnostic value of non-phosphorylated tau fraction (p-tau Goossens J; Bjerke M; Struyfs H; Niemantsverdriet E; Somers C; Van den Bossche T; Van Mossevelde S; De Vil B; Sieben A; Martin JJ; Cras P; Goeman J; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S Alzheimers Res Ther; 2017 Jul; 9(1):49. PubMed ID: 28709448 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543 [TBL] [Abstract][Full Text] [Related]
12. Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. Niemantsverdriet E; Feyen BFE; Le Bastard N; Martin JJ; Goeman J; De Deyn PP; Bjerke M; Engelborghs S J Alzheimers Dis; 2018; 63(1):373-381. PubMed ID: 29614653 [TBL] [Abstract][Full Text] [Related]